Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Stahl

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Cancer|February 14, 2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applicationsMaximilian Stahl, Amer M Zeidan
Current Oncology Reports|March 25, 2019
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic TargetsMaximilian Stahl, Aaron D Goldberg
British Journal of Haematology|August 15, 2019
Differentiation syndrome in acute promyelocytic leukaemiaMaximilian Stahl, Martin S Tallman
Expert Review of Hematology|April 12, 2017
Management of myelofibrosis: JAK inhibition and beyondMaximilian Stahl, Amer M Zeidan
Expert Review of Hematology|March 10, 2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trendsMaximilian Stahl, Amer M Zeidan
Leukemia & Lymphoma|December 18, 2019
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for allMaximilian Stahl, Martin S Tallman
Blood|September 5, 2024
TP53-mutated acute myeloid leukemia: how can we improve outcomes?David A Sallman, Maximilian Stahl
American Journal of Hematology|February 12, 2025
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and ManagementShai Shimony, Maximilian Stahl, Richard M Stone
American Journal of Hematology|January 3, 2023
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and managementShai Shimony, Maximilian Stahl, Richard M Stone
Expert Opinion on Emerging Drugs|August 4, 2016
Emerging biological therapies for the treatment of myelodysplastic syndromesAmer M Zeidan, Maximilian Stahl, Rami Komrokji
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Cancer|February 14, 2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applicationsMaximilian Stahl, Amer M Zeidan
Current Oncology Reports|March 25, 2019
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic TargetsMaximilian Stahl, Aaron D Goldberg
British Journal of Haematology|August 15, 2019
Differentiation syndrome in acute promyelocytic leukaemiaMaximilian Stahl, Martin S Tallman
Expert Review of Hematology|April 12, 2017
Management of myelofibrosis: JAK inhibition and beyondMaximilian Stahl, Amer M Zeidan
Expert Review of Hematology|March 10, 2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trendsMaximilian Stahl, Amer M Zeidan
Leukemia & Lymphoma|December 18, 2019
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for allMaximilian Stahl, Martin S Tallman
Blood|September 5, 2024
TP53-mutated acute myeloid leukemia: how can we improve outcomes?David A Sallman, Maximilian Stahl
American Journal of Hematology|February 12, 2025
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and ManagementShai Shimony, Maximilian Stahl, Richard M Stone
American Journal of Hematology|January 3, 2023
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and managementShai Shimony, Maximilian Stahl, Richard M Stone
Expert Opinion on Emerging Drugs|August 4, 2016
Emerging biological therapies for the treatment of myelodysplastic syndromesAmer M Zeidan, Maximilian Stahl, Rami Komrokji
Pageof 12